Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors

Lorusso, Loredana; Romei, Cristina; Piaggi, Paolo; Fustini, Chiara; Molinaro, Eleonora; Agate, Laura; Bottici, Valeria; Viola, David; Pellegrini, Giovanni; Elisei, Rossella

doi:10.1089/thy.2020.0060

Cited by 14 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These authors urge consideration Ca 19.9 secretion and doubling time as criteria for initiating systemic therapy independent of progressive structural disease. 23 …”

Section: Resultsmentioning

confidence: 99%

“… 52 More recent reports suggest that rapidly progressive disease may be defined either structurally with RECIST criteria or with biochemical markers. 20 , 23 …”

Section: Resultsmentioning

confidence: 99%

“…These authors urge consideration Ca 19.9 secretion and doubling time as criteria for initiating systemic therapy independent of progressive structural disease. 23 Procalcitonin. Procalcitonin is the peptide precursor molecule of calcitonin, produced in response to inflammation, and is used in clinical practice to diagnose sepsis.…”

Section: Diagnostic Laboratory Studiesmentioning

confidence: 99%

“…52 More recent reports suggest that rapidly progressive disease may be defined either structurally with RECIST criteria or with biochemical markers. 20,23 Cabozantinib and vandetanib were the first two FDA-approved MKIs for treatment of progressive or symptomatic MTC with locally advanced or metastatic disease. Both are small molecule inhibitors that target RET and vascular endothelial growth factor-2 (VEGF-2) by blocking both angiogenic and proliferative pathways.…”

Section: Imagingmentioning

confidence: 99%

See 3 more Smart Citations

Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis

Bartz-Kurycki

Oluwo

Morris‐Wiseman

2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor that represents <5% of all thyroid malignancies and is generally more aggressive than differentiated thyroid cancer. The aim of this study is to provide an update, through review of clinical studies of patients with MTC published between January 1, 2016, and June 1, 2021, on recent advances in the diagnosis and treatment of MTC. This review focuses on updates in biochemical testing, imaging, hereditary disease, surgical management, adjuvant therapies, and prognosis. Recent advances reviewed herein have sought to diagnose MTC at earlier stages of disease, predict when patients with a hereditary syndrome may develop MTC, use functional imaging to assess for distant metastases, perform optimal initial surgery with appropriate lymphadenectomy, employ targeted systemic therapies for patients with progressive metastatic disease, and better predict patient-specific outcomes.

show abstract

“…These authors urge consideration Ca 19.9 secretion and doubling time as criteria for initiating systemic therapy independent of progressive structural disease. 23 …”

Section: Resultsmentioning

confidence: 99%

“… 52 More recent reports suggest that rapidly progressive disease may be defined either structurally with RECIST criteria or with biochemical markers. 20 , 23 …”

Section: Resultsmentioning

confidence: 99%

Section: Diagnostic Laboratory Studiesmentioning

confidence: 99%

Section: Imagingmentioning

confidence: 99%

See 2 more Smart Citations

Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis

Bartz-Kurycki

Oluwo

Morris‐Wiseman

2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…Based on them, it is possible to classify the patient into a group with stable or progressive disease [ 19 ]. The prognosis of mortality in patients with advanced MTC may be assessed with serum Ca9.9 positivity and doubling time [ 20 ]. Hajje et al [ 21 ] report that CEA may also be used as a predictive biomarker.…”

Section: Introductionmentioning

confidence: 99%

Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Kaliszewski

Ludwig

et al. 2022

Cancers

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a neoplasm originating from parafollicular C cells. MTC is a rare disease, but its prognosis is less favorable than that of well-differentiated thyroid cancers. To improve the prognosis of patients with MTC, early diagnosis and prompt therapeutic management are crucial. In the following paper, recent advances in laboratory and imaging diagnostics and also pharmacological and surgical therapies of MTC are discussed. Currently, a thriving direction of development for laboratory diagnostics is immunohistochemistry. The primary imaging modality in the diagnosis of MTC is the ultrasound, but opportunities for development are seen primarily in nuclear medicine techniques. Surgical management is the primary method of treating MTCs. There are numerous publications concerning the stratification of particular lymph node compartments for removal. With the introduction of more effective methods of intraoperative parathyroid identification, the complication rate of surgical treatment may be reduced. The currently used pharmacotherapy is characterized by high toxicity. Moreover, the main limitation of current pharmacotherapy is the development of drug resistance. Currently, there is ongoing research on the use of tyrosine kinase inhibitors (TKIs), highly specific RET inhibitors, radiotherapy and immunotherapy. These new therapies may improve the prognosis of patients with MTCs.

show abstract

Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma

et al. 2023

View full text Add to dashboard Cite

Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors

Cited by 14 publications

References 23 publications

Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis

Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis

Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma

Contact Info

Product

Resources

About